The DNA Medicine Institute received a $1.5 million grant from the NIH to aid in the development of its fingerstick point-of-care technology that monitors Helimbra, or emicizumab, and factor VIII blood levels in people with hemophilia A. The device could be especially useful in developing countries.
Company receives $1.5M grant for FVIII, emicizumab test
Sign up for Sigma Xi SmartBrief
News on scientific research and innovation
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.